Qsymia Capsule, Extended Release
Product Images NDC 62541-201

Product Visual Gallery

This gallery contains 9 technical images submitted to the FDA as part of the official labeling for Qsymia (NDC 62541-201). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Vivus Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Table 1 (Qsymia 01)

This appears to be a table with measured weights and corresponding heights in kilograms and centimeters. The first row seems to list the weights in increasing order, while the following rows list the height values in centimeters for various weight measurements.*

FDA Label Image

Chemical Structure (Qsymia 02)

FDA Label Image

Chemical Structure (Qsymia 03)

FDA Label Image

Studies 1 And 2 (Qsymia 04)

This appears to be a table or chart displaying results from two different studies. It includes information about several different doses of a drug called Qsymia compared to a placebo, with data on the number of participants and time points for each group. The results show a statistically significant difference between Qsymia and placebo across all doses and time points.*

FDA Label Image

Figures A-d (Qsymia 05)

This text describes different dosages and appearances of Qsymia medication. The medication comes in capsule form, with varying strengths of active ingredients indicated by the numbers in the parentheses. Each capsule has a different color, either purple or yellow, with white or black printing on the capsule body. Figure A is not described other than its appearance, while Figures B, C, and D represent increasing doses of the medication.*

FDA Label Image

Principal Display Panel (3.75 mg/23 mg Capsule Bottle Label)

This is a description of a medication called SOF-TTF, which comes in the form of capsules in a purple and yellow color. The capsules contain 7.5 mg/46 mg of phentermine and topiramale exerted-release. The medication needs to be stored at room temperature, protected from moisture, and kept out of reach of children. The package carries a NDC NUMBER 62541-202-30 and should be dispensed with medication guide. For further information about dosage and prescribing, the user may refer to the accompanying product literature.*

FDA Label Image

Principal Display Panel (7.5 mg/46 mg Capsule Bottle Label)

This text is a label of a medication called Qsymia. It provides information about the medicine such as storage instructions, dosage, and prescribing information. The medication is in capsule form, the color of which is described as purple/purple with "VIVUS" printed in white on the cap and "3.75723" printed in white on the body. This medication is for adult use only and should be kept away from children. The NDC number for this medicine is 62541-201-30.*

FDA Label Image

Principal Display Panel (15 mg/92 mg Capsule Bottle Label)

This is a description for Qsymia, a medication in capsule form. The capsules should be stored at room temperature and protected from moisture. They come in a container of 30 capsules, and the yellow cap has "VIVUS" printed in black, while the white body has "15/92" printed in black. The medication is intended for weight loss and contains phentermine and topiramate extended-release. For additional information regarding dosage and prescribing, consult the accompanying product literature.*

FDA Label Image

Principal Display Panel (11.25 mg/69 mg Capsule Bottle Label)

This is the description of Qsymia medication in capsule form with 11.25 mg/69 strength. The capsules are yellow with "VIVUS" printed in black on the cap and "11.25/69" on the body. They must be stored at room temperature, protected from moisture and kept out of reach of children. For dosage and other information, refer to the accompanying product literature.*

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.